Cybin (HELP) Net Income (2020 - 2025)
Cybin's (HELP) quarterly Net Income came in at -$42.7 million in Q4 2025, down 465.4% YoY from $11.7 million in Q4 2024, and down 26.53% on a QoQ basis from -$33.7 million in Q3 2025.
Cybin (HELP) Net Income (2020 - 2025) Analysis & Trends
Cybin (HELP) has 6 years of Net Income data on file, last reported at -$42.7 million in Q4 2025.
- Quarterly Net Income fell 465.4% year-over-year to -$42.7 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$101.0 million (down 67.47% YoY) and the FY2026 annual result came in at -$147.8 million, down 53.91% from the prior year.
- Net Income retreated to -$42.7 million in Q4 2025, from -$33.7 million in the prior quarter.
- In the past five years, Net Income ranged from a high of $32.0 million in Q1 2022 to a low of -$42.7 million in Q4 2025.
- A 5-year average of -$12.2 million and a median of -$10.8 million in 2024 frame the typical range for Net Income.
- Annual changes were most pronounced in 2021 — Net Income slumped 600.72% — and 2024, when it jumped 66.13%.
- Tracing HELP's Net Income over 5 years: stood at -$13.7 million in 2021, then jumped by 42.04% to -$7.9 million in 2022, then slumped by 181.52% to -$22.3 million in 2023, then surged by 66.13% to -$7.5 million in 2024, then sank by 465.4% to -$42.7 million in 2025.
- The last three Net Income figures came in at -$42.7 million (Q4 2025), -$33.7 million (Q3 2025), and -$24.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Cybin | 417.29 Mn | 417.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -42.67 Mn |
| Sep 30, 2025 | -33.72 Mn |
| Jun 30, 2025 | -24.61 Mn |
| Dec 31, 2024 | -7.55 Mn |
| Sep 30, 2024 | -41.92 Mn |
| Jun 30, 2024 | -10.84 Mn |
| Dec 31, 2023 | -22.28 Mn |
| Sep 30, 2023 | -8.87 Mn |
| Jun 30, 2023 | -10.80 Mn |
| Feb 28, 2023 | 8.11 Mn |
| Dec 31, 2022 | -7.91 Mn |
| Sep 30, 2022 | -7.65 Mn |
| May 31, 2022 | 4.55 Mn |
| Feb 28, 2022 | 32.01 Mn |
| Dec 31, 2021 | -13.65 Mn |
| Sep 30, 2021 | -13.99 Mn |
| Jun 30, 2021 | -11.97 Mn |
| Mar 31, 2021 | -5.24 Mn |
| Dec 31, 2020 | -8.76 Mn |
| Sep 30, 2020 | -2.00 Mn |